Renal Cell Carcinoma Metastatic
Conditions
Brief summary
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
Interventions
DRUGJMKX003948
Subjects will receive JMKX003948 tablets until disease progression
Sponsors
Zhejiang Hangyu Pharmaceutical Co., Ltd.
Jemincare
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Has the ability to understand and willingness to sign a written informed consent form. 2. Male or female from 18 years of age or older. 3. Histologically confirmed locally advanced or metastasis clear cell renal cell carcinoma. 4. Has at least one measurable lesion per RECIST v1.1. 5. Has a life expectancy of ≥ 12 weeks. 6. Adequate organ function.
Exclusion criteria
1. Patients with known active CNS metastases and/or cancerous meningitis. 2. Has received any type of systemic anticancer monoclonal antibodies or other immunosuppressants within 4 weeks prior to the first dose. Has received prior chemotherapy, targeted therapy, or other investigational therapy within 2 weeks prior to the first dose. 3. Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy. 4. Has impaired heart function,or clinically significant cerebrovascular and cardiovascular disease. 5. Subjects with dysphagia or known drug absorption disorders. 6. Has a history of any other malignancy within 5 years. 7. Has severe oncological complications. 8. Is currently participating in other clinical studies. 9. Subjects with be unsuitable for participation in the trial evaluated by investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation: Number of participants with dose limiting toxicities (DLTs) | Up to 2 months | Number of participants with DLTs |
| Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | Up to 2 years | Number of participants with AEs/SAEs to characterize the safety and tolerability of JMKX003948. |
| Dose Expansion: Objective Response Rate (ORR) | Up to 1 year | ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| maximum plasma concentration (Cmax) | Up to 1 month | Maximum observed concentration. |
| maximum plasma concentration (Tmax) | Up to 1 month | Time to reach maximum observed plasma concentration. |
| Duration of Response (DoR) | Up to 1 year | DoR is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first. |
Countries
China
Contacts
Primary ContactHuihui Xiang
Outcome results
None listed